Anti-GnRH recombinant plasmid, anti-GnRH mRNA vaccine and application thereof
Through the dual-gene expression technology of anti-GnRH recombinant plasmid and KISS1 gene, combined with lipid nanoparticles to encapsulate mRNA, stimulates immune response, and solves the problem of surgical castration damage to animals and poor gene immune castration, and realizes reproductive function Effective regulation and hormone-dependent tumor treatment.
Patent Information
- Application Number
- CN202411124178.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-26
AI Technical Summary
The existing surgical castration method causes strong stress response and permanent gonadal trauma to animals, and the operation is complex. Although the gene immunocastration method is simple, its effect is limited and it cannot effectively replace the traditional castration method.
Develop an anti-GnRH recombinant plasmid, combining GnRH and KISS1 genes through dual-gene expression technology to construct an anti-GnRH mRNA vaccine, and use lipid nanoparticles to encapsulate mRNA, stimulate the body's immune response, produce specific antibodies, and block the physiological effects of GnRH , thereby achieving regulation of reproductive function.
This vaccine can effectively replace surgical castration, reduce aggressive behavior of public animals, improve meat quality and feed utilization, reversibly control pet reproductive behavior in pet medical care, improve pet owner's quality of life, and is medically used for hormone-dependent tumor treatment.
Smart Images

Figure CN119020413A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to an anti-GnRH recombinant plasmid, an anti-GnRH mRNA vaccine and applications thereof. Background Art
[0002] The castration methods used today mainly include surgical castration, chemical castration, and immunocastration. However, surgical castration, which is the most widely used method, can easily cause strong stress reactions and permanent gonadal trauma to animals during the operation. Genetic immunocastration is achieved by injecting DNA / RNA of a certain exogenous reproductive hormone into animals, indirectly inducing the body to produce specific antibodies that can neutralize the hormone, thereby achieving the purpose of artificially changing the reproductive axis regulation function. Immunocastration is simple to operate, can minimize damage to the animal body, and does not affect the production performance of the animal.
[0003] mRNA can be translated into proteins in the body and can be used for vaccination. An especially important advantage of mRNA technology is that mRNA can be used as a template for protein translation. Compared with traditional vaccines, mRNA vaccines have the advantages of short R&D cycle, simple production, reliable safety, etc., while also being able to induce a comprehensive immune response in the body. Compared with DNA vaccines or certain viral vector vaccines, mRNA vaccines will not be integrated into the DNA of the vaccinated population, causing the risk of insertion mutations. Therefore, in the near future, mRNA vaccines will not only become an important means for humans to prevent and treat diseases, but will also serve the development of pet medicine and animal husbandry.
[0004] Gonadotropin-releasing hormone (GnRH), synthesized by neurons in the hypothalamus, can selectively promote the synthesis and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) in the distal part of the pituitary gland, thereby affecting the function of the ovaries of female animals and the testicles of male animals. In addition, studies have shown that its regulatory effect is dualistic. Appropriate doses of GnRH can promote the secretion and release of LH and FSH, but large doses of exogenous GnRH or GnRH analogs will inhibit the function of the reproductive system of the body. This function of GnRH allows it to be used as an immunogen for active immunization to achieve the purpose of regulating animal reproduction, mainly for castration of animals. In addition, studies have shown that GnRH immunization can also be used to treat some hormone-dependent cancers in humans. Therefore, the development of a GnRH vaccine is of broad significance, and the development of an effective GnRH vaccine has become the goal pursued by many vaccine researchers.
[0005] The kisspeptin 1 (KISS1) gene can encode a 145 amino acid neuropeptide precursor, which is sheared and cleaved to form kisspeptin-10 / 13 / 14. Studies have shown that these three polypeptides can specifically bind to the G protein-coupled receptor (GPR54), regulate the activity of hypothalamic neurons to secrete GnRH, change the release of LH and FSH, and then regulate the secretion of downstream hormones to achieve the purpose of regulating the reproductive physiological activities of animals. Therefore, the present invention combines GnRH and KISS1 to co-express the two genes, further enhance the castration effect, and construct a new type of immune castration vaccine. Summary of the invention
[0006] The purpose of the present invention is to combine GnRH and KISS1 to perform co-expression of the two genes and provide an mRNA vaccine against GnRH.
[0007] To this end, the present invention provides an anti-GnRH recombinant plasmid, comprising a plasmid vector, and a GnRH sequence and a KISS sequence inserted into the plasmid vector; the KISS1 sequence is connected to the 5' end of the GnRH sequence.
[0008] Specifically, the plasmid vector is inserted with four GnRH sequences connected by a flexible GS Linker; the repeated GnRH amino acid sequence containing the GS Linker is shown in SEQ ID NO.3.
[0009] Specifically, the 5' end of the fourth GnRH sequence is inserted with a t-PA signal peptide sequence, a PADRE sequence and a KISS1 sequence; the amino acid sequence of the t-PA signal peptide is shown in SEQ ID NO.4; the amino acid sequence of PADRE is shown in SEQ ID NO.5; and the KISS1 sequence is shown in SEQ ID NO.6.
[0010] Specifically, the above-mentioned plasmid vector is the eukaryotic plasmid vector pVAX1.
[0011] The present invention also provides an anti-GnRH mRNA vaccine, comprising mRNA prepared by using the above anti-GnRH recombinant plasmid; the mRNA sequence is shown as SEQ ID NO.7.
[0012] Specifically, the above-mentioned anti-GnRH mRNA vaccine also includes lipid nanoparticles.
[0013] Specifically, the lipid nanoparticles include SM102, DSPC, cholesterol and PEG2000-DMG in a molar ratio of 50:10:38.5:1.5.
[0014] The present invention also provides a method for preparing an anti-GnRH mRNA vaccine, comprising the following steps: preparing an anti-GnRH recombinant plasmid, performing enzyme linearization treatment, using the plasmid as an in vitro transcription template for an in vitro transcription reaction, and encapsulating the obtained mRNA using lipid nanoparticles to obtain an anti-GnRH mRNA vaccine.
[0015] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0016] The anti-GnRH recombinant plasmid provided by the present invention uses transferrin as an immune vector, inserts the KISS1 gene and 4 segments of GnRH repeat sequences, integrates them into the coding region of the eukaryotic plasmid vector to obtain a recombinant plasmid, and then uses the constructed eukaryotic expression vector for linearization treatment using a restriction endonuclease, and uses it as an in vitro transcription template to obtain mRNA, which can be used to prepare an anti-GnRH mRNA vaccine expressing a double gene. The GnRH mRNA vaccine is directly used to immunize animals, and transferrin with KISS1 protein and 4 segments of GnRH repeat polypeptides is expressed in vivo through the translation system of the host cell, stimulating the body's immune response and producing GnRH-specific antibodies. The anti-GnRH antibody can combine with endogenous GnRH in the body to block the physiological effects of GnRH. In medicine, GnRH mRNA vaccine can be used to treat hormone-dependent tumors such as prostate cancer; in animal husbandry, the vaccine can be used to replace surgical castration to control the reproduction of livestock and poultry, reduce the aggressive behavior of male animals, and improve meat quality and feed utilization; in pet medicine, the vaccine can be used to replace surgical castration to reversibly control the reproduction of pets, avoid the sexual behavior of pets (such as howling, spraying urine, etc.), and improve the quality of life of pet owners. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 This is a structural framework diagram of the eukaryotic expression plasmid vector pVAX1-GnRH.
[0018] Figure 2 This is a structural framework diagram of the eukaryotic expression plasmid vector pVAX1-KISS1-GnRH.
[0019] Figure 3 It is the denaturing gel electrophoresis diagram of mRNA obtained by in vitro transcription; M is the standard molecular weight RNA; 1 / 2 is the electrophoresis result of GnRH; 3 / 4 is the electrophoresis result of KISS1-GnRH.
[0020] Figure 4 The weight of immunized mice.
[0021] Figure 5 It is the result of antibody titer test of immunized mice.
[0022] Figure 6These are the test results of serum testosterone in immunized male mice.
[0023] Figure 7 It is the testis index and ovary index of immunized mice.
[0024] Figure 8 These are the results of histopathological examination of the testicles and ovaries of immunized mice. DETAILED DESCRIPTION
[0025] The technical scheme in the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Although the representative embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes can be made to the present invention without departing from the scope of the present invention. Therefore, the scope of the present invention should not be limited to the embodiments, but should be limited by the attached claims and their equivalents.
[0026] The present invention provides an anti-GnRH recombinant plasmid, comprising a plasmid vector, preferably a eukaryotic plasmid vector pVAX1, and a GnRH sequence and a KISS sequence inserted into the plasmid vector; the KISS1 sequence is connected to the 5' end of the GnRH sequence; GnRH is a 10-peptide hormone composed of 9 amino acids, and the amino acid sequence of GnRH is shown in SEQ ID NO.1.
[0027] SEQ ID NO.1:GluHisTrpSerTyrGlyLeuArgProGly
[0028] Studies have shown that immunogens containing multiple copies of currently linked self-peptide sequences can greatly improve immunogenicity. In order to improve the immunogenicity of GnRH, the gene encoding four segments of GnRH repeat sequences was inserted into the eukaryotic plasmid vector used. The four GnRH sequences were all connected by a flexible GS Linker. The amino acid sequence of GS Linker is shown in SEQ ID NO.2, and the amino acid sequence of four segments of GnRH repeats containing GS Linker is shown in SEQ ID NO.3.
[0029] SEQ ID NO.2: GlyGlyGlyGlySerGlyGlyGlyGlySer
[0030] SEQ ID NO.3:
[0031] GluHisTrpSerTyrGlyLeuArgProGly GlyGlyGlyGlySerGlyGlyGlyGlySer GluHisTrpSerTyrGlyLeuArgProGly GlyGlyGlyGlySerGlyGlyGlyGlySerGluHisTrpSerTyrGlyLeuArgProGly GlyGlyGlyGlySerGlyGlyGlyGlySer GluHisTrpSerTyrGlyLeuArgProGly (GSLinker is underlined).
[0032] In addition to the basic elements of the eukaryotic expression vector, the anti-GnRH recombinant plasmid also includes t-PA signal peptide and PADRE to ensure the expression and secretion of exogenous GnRH and enhance the immune response of GnRH in vivo. The t-PA signal peptide sequence, PADRE sequence and KISS1 sequence are inserted into the 5' end of the 4th GnRH sequence; the amino acid sequence of the t-PA signal peptide is shown in SEQ ID NO.4; the amino acid sequence of PADRE is shown in SEQ ID NO.5; and the amino acid sequence of KISS1 is shown in SEQ ID NO.6. The inserted exogenous genes are connected with a flexible GS Linker to allow the proteins on both sides to complete their independent functions.
[0033] SEQ ID NO.4:
[0034] MetAspAlaMetLysArgGlyLeuCysCysValLeuLeuLeuCysGlyAlaValPheVal SerPro
[0035] SEQ ID NO.5: AlaLysPheValAlaAlaTrpThrLeuLysAlaAlaAla
[0036] SEQ ID NO.6:
[0037] MNALVFWQLMFFLWATSFKETLEKVAPMENPRSTGPRPIPPPLQAPWEQGPRCAERKPAAAEANPRGTSSCQPPESSSGPQRPGLCTPRSRLIPAPRGAVLV QREKDLSAYNWNSFGLRYGKRQAAPPGSRNQGAGRD
[0038] GnRH is an autoantigen. Simply introducing the GnRH gene for expression in vivo may not be able to stimulate the body to produce corresponding antibodies. Therefore, like protein vaccines, it must be coupled with a macromolecular carrier protein and expressed in vivo to further enhance the immunogenicity of GnRH and break immune tolerance. Therefore, the gene encoding transferrin is connected to the 3' end of the fourth segment of GnRH.
[0039] The present invention also provides an anti-GnRH mRNA vaccine, which comprises mRNA prepared using the above-mentioned anti-GnRH recombinant plasmid; the sequence of the mRNA is as shown in SEQ ID NO.7.
[0040] SEQ ID NO.7:
[0041] AUGGACGCCAUGAAGCGCGGCCUGUGCUGCGUGCUGCUCCUGUGC
[0042] GGCGCCGUGUUUGUCAGCCCCGCCAAAUUCGUCGCUGCUUGGACAC
[0043] UCAAAGCCGCCGCUGGCGGAGGUGGCAGCGGCGGUGGGGGCUCCA
[0044] UGAACGCCCUGGUGUUCUGGCAGCUGAUGUUCUUCCUGUGGGCCA
[0045] CAAGCUUCAAGGAGACACUGGAAAAAGUCGCCCCCAUGGAGAAUC
[0046] CCCGCAGCACCGGCCCCCGGCCUAUCCCCCCUCCCCUGCAAGCCCCC
[0047] UGGGAACAAGGCCCUCGGUGUGCCGAACGCAAGCCUGCCGCUGCCG
[0048] AGGCCAAUCCCCGGGGGACAAGCAGCUGUCAGCCCCCCGAAAGCAG
[0049] CAGCGGCCCUCAGCGCCCUGGCCUGUGCACCCCCCGGAGCCGCCUG
[0050] AUCCCCGCCCCCCGGGGCGCCGUGCUGGUGCAGCGCGAGAAGGACC
[0051] UGAGCGCCUACAACUGGAACUCCUUCGGGCUGCGGUACGGGAAGC
[0052] GGCAAGCCGCUCCCCCUGGGAGCCGGAACCAAGGCGCCGGCCGGGA
[0053] CGGCGGCGGGGGCAGCGGCGGGGGCGGCAGCCAACACUGGAGCUA
[0054] CGGGCUGCGGCCCGGCGGCGGAGGAGGCAGCGGAGGCGGAGGUUC
[0055] CGAACACUGGUCCUACGGGCUGCGCCCCGGAGGCGGUGGAGGCUCC
[0056] GGCGGAGGUGGCUCCGAACACUGGUCCUAUGGCCUCCGGCCCGGGG
[0057] GCGGUGGCGGCUCCGGCGGCGGAGGCAGCGAACACUGGUCCUACG
[0058] GCCUCCGCCCUGGAGGAGGUGGUGGAAGCGGCGGCGGUGGCUCCC
[0059] UCAGCAAGGACAUCAUCAAGCUGCUGAACGAGCAAGUGAACAAGG
[0060] AGAUGAACAGCAGCAACCUGUACAUGAGCAUGAGCAGCUGGUGCU
[0061] ACACCCACAGCCUGGACGGCGCCGGCCUGUUCCUGUUCGACCACGC
[0062] CGCCGAGGAGUACGAGCACGCCAAGAAGCUGAUCAUCUUCCUGAA
[0063] CGAGAACAACGUGCCCGUGCAGCUGACAAGCAUCAGCGCCCCCGAG
[0064] CACAAGUUCGAGGGCCUGACACAGAUCUUUCAGAAGGCCUACGAG
[0065] CACGAGCAGCACAUCAGCGAGGAGCAUCAACAACAUCGUGGACCACG
[0066] CCAUCAAGAGCAAGGACCACGCCACCUUCAACUUCCUGCAGUGGUA
[0067] CGUGGCCGAGCAGCACGAGGAAGAGGGUGCUGUUCAAGGACAUCCU
[0068] GGACAAGAUCGAGCUGAUCGGCAACGAGAACCACGGCCUGUACCU
[0069] GGCCGAUCAGUACGUGAAGGGCAUCGCCAAGAGCCGCAAGAGCGG
[0070] CGGCGGGGGCAGCGGCGGGGGCGGCAGCCACCAUCACCAUCACCAC
[0071] GGCGGCAGC
[0072] Furthermore, the anti-GnRH mRNA vaccine further comprises lipid nanoparticles. The lipid nanoparticles preferably comprise SM102, DSPC, cholesterol and PEG2000-DMG in a molar ratio of 50:10:38.5:1.5.
[0073] The present invention also provides a method for preparing an anti-GnRH mRNA vaccine, comprising the following steps: preparing an anti-GnRH recombinant plasmid, performing enzyme linearization treatment, using the plasmid as an in vitro transcription template for an in vitro transcription reaction, and encapsulating the obtained mRNA using lipid nanoparticles to obtain an anti-GnRH mRNA vaccine.
[0074] The effects of an anti-GnRH recombinant plasmid, an anti-GnRH mRNA vaccine and their application of the present invention are studied below through specific examples.
[0075] In the examples of the present invention, operations such as plasmid extraction, endonuclease digestion, RNA purification, DNA fragment recovery, and DNA transformation into Escherichia coli all adopt conventional operating methods in the art.
[0076] Embodiment 1:
[0077] 1. Transformation of eukaryotic plasmids pVAX1-GnRH and pVAX1-KISS1-GnRH
[0078] The gene fragments of GnRH, KISS1 and transferrin were synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd. The gene fragments encoding 4 segments of GnRH repeat sequences, KISS1 gene and transferrin were inserted into the eukaryotic plasmid pVAX1 vector, which was obtained by puncturing bacteria. Take a clean pipette tip and insert it along the growth line of Escherichia coli Escherichiacoli DH-5α in the puncture tube, and operate back and forth several times to increase the contact surface. The tip stained with bacteria was streaked on the LB plate containing kanamycin and cultured overnight. The next day, a single clone was picked from the LB plate and inoculated into the LB liquid culture medium containing kanamycin, and cultured overnight at 37°C in a shaking incubator. Then the extracted plasmid was sent to Shenzhen Qingke Biotechnology Co., Ltd. for sequencing. The plasmid with confirmed results was digested at 37°C using Xbal1 restriction endonuclease. After 4 hours, the reaction product was gel-recovered and purified for in vitro transcription template. The structural framework of the eukaryotic expression plasmid vector pVAX1-GnRH and pVAX1-KISS1-GnRH is as follows Figure 1-2 shown.
[0079] 2. In vitro transcription mRNA synthesis, purification and mRNA-LNP preparation
[0080] In vitro transcription was performed using in vitro transcription reagents from Wuhan Hanhai New Enzyme Biotechnology Co., Ltd. and Wuhan Tangzhi Pharmaceutical Co., Ltd. Taking a 20 μL reaction system as an example, after reacting at 37°C for 2 hours, 1 μL DNase 1 was added and incubated at 37°C for 15 minutes to remove dsDNA.
[0081] Add 1 / 10 volume of 3mol / L sodium acetate buffer to the obtained mRNA mixture to make the final concentration of sodium acetate 0.3mol / L, invert and mix, accurately add 2 volumes of pre-cooled anhydrous ethanol, invert and mix, centrifuge at -20℃ for 30 minutes to obtain the white precipitate which is RNA, wash the precipitate with 70% ethanol prepared with DEPC, and add appropriate DEPC water according to the amount of precipitate to dissolve the precipitate. The mRNA obtained by in vitro transcription was subjected to denaturing gel electrophoresis, and the results are as follows: Figure 3 shown.
[0082] The obtained mRNA was diluted with 50 mM citrate buffer (pH 4.0) to a concentration of 0.1 mg / ml, and then the diluted mRNA was mixed and encapsulated with a lipid mixture (including SM102, DSPC, cholesterol and PEG2000-DMG in a molar ratio of 50:10:38.5:1.5) at a ratio of 1:3 (volume ratio) using the nanodrug preparation system Inano E. The total flow rate was set to 12 ml / min. The encapsulation efficiency results are shown in Table 1.
[0083] Add the packaged mRNA Ultra-15 ultrafiltration tube, add an equal amount of PBS (pH 7.4), centrifuge at 3000g for 30 minutes, a total of 3 times to remove ethanol, and finally sterilize through a 0.22μm sterile filter. The prepared mRNA-LNP was stored at 4°C before use.
[0084] Table 1 Particle size and encapsulation efficiency of GnRH-LNP and KISS1-GnRH-LNP
[0085]
[0086] Embodiment 2:
[0087] Female and male mice (BALB / c) around 6 weeks old were divided into pVAX1-KISS1-GnRH-LNP experimental group, pVAX1-GnRH-LNP control group and LNP negative control group, with 12 mice in each group. The mice in each group were immunized with the same dose each time, 100 μL (containing 10 μg) per mouse, and the inoculation method was leg muscle injection.
[0088] The second immunization was performed 14 days after the first immunization. The mice were weighed and recorded at 0, 2, 4, 6, and 10 weeks after the first immunization ( Figure 4 ) and collect blood from the retinal venous plexus to separate serum, which is stored at -20℃ for testing.
[0089] 1. ELISA test for GnRH antibodies
[0090] The hapten (peptide) was coupled to the numerous primary amines in the carrier protein KLH by the crosslinking agent EDC, and the hapten-KLH complex was coated into a 96-well ELISA plate at 4°C overnight, with 200 μg of the complex added to each well. After coating, the wells were blocked with 5% bovine serum albumin (BSA) solution at 37°C for 1 hour. The GnRH peptide used for hapten ELISA detection was synthesized by GenScript Biotech Co., Ltd., and the amino acid sequence is as follows: GluHisTrpSerTyrGlyLeuArgProGly.
[0091] The antibody serum obtained from each group (selected 4 weeks and 10 weeks after the first immunization) was diluted 100, 300, 900, 2700, 8100 and 24300 times with PBS at pH 7.5, and then 100 μL of the diluted serum was added to each well and reacted at 37°C for 1 hour, and washed 3 times with PBST (containing 0.05% Tween-20), each time for 5 minutes; then 100 μL of 1:500 diluted horseradish peroxidase-labeled goat anti-mouse IgG secondary antibody was added to each well, and reacted at 37°C for 1 hour, and washed 3 times with PBST (containing 0.05% Tween-20), each time for 5 minutes; then 100 μL of TMB colorimetric solution was added, and reacted at 37°C for 20 minutes, and 100 μL of TMB colorimetric stop solution was added to terminate the reaction, and the absorbance value of each well was measured at a wavelength of 450 nm. The results of mouse serum antibody titer are shown in the figure. Figure 5 It can be seen that specific anti-GnRH antibodies were produced in the mice of the pVAX1-KISS1-GnRH-LNP experimental group.
[0092] 2. Study on the immunocastration effect of anti-GnRH mRNA vaccine
[0093] Blood was collected from the fundus venous plexus of each group at 0, 2, 4, 6, and 10 weeks after the first immunization, and serum testosterone levels were tested. The results are as follows: Figure 6 , the serum testosterone level in mice in the pVAX1-KISS1-GnRH-LNP experimental group was lower than that in the control group.
[0094] Six weeks after the first immunization, the immunocastrated mice were caged with healthy, non-immunized 6-8 week old mice (immune castrated male mice were caged with non-immune female mice; immune castrated female mice were caged with non-immune male mice), and the sexual behaviors (sniffing, chasing, etc.) of all experimental animals were observed for 30 minutes each time for one week. The female mice were observed to see whether they were pregnant and gave birth 35 days after caged together. The results showed that the pregnancy rate of female mice in the LNP negative control group and female mice caged with immunocastrated male mice was 100%, the pregnancy rate of female mice in the pVAX1-GnRH-LNP control group and female mice caged with immunocastrated male mice was 16.7%, and the pregnancy rate of female mice in the pVAX1-KISS1-GnRH-LNP experimental group and female mice caged with immunocastrated male mice was 8.3%.
[0095] Ten weeks after the first immunization, mice in each group were killed, and the testicles of male mice were separated and weighed, and the ovaries of female mice were separated and weighed. The testicle / ovary ratio of each group is shown in Figure 7 After weighing, the testicles / ovaries were fixed in 4% paraformaldehyde at room temperature for 1 day and then sent to Wuhan Saiweier Biotechnology Co., Ltd. for gonadal HE staining and photography. The analysis results are as follows Figure 8As shown, it can be seen that compared with the control group, the number of sperm cells (blue arrows) in the seminiferous tubules in the testicular tissue of male mice in the experimental group was significantly reduced; the number of follicle cells (blue arrows) in the ovarian tissue of female mice in the experimental group was significantly reduced.
[0096] The above examples are merely illustrative of the present invention and do not constitute a limitation on the protection scope of the present invention. All designs that are the same or similar to the present invention fall within the protection scope of the present invention.
Claims
1. A recombinant plasmid for resisting GnRH, Features: It comprises a plasmid vector, and a GnRH sequence and a KISS sequence inserted into the plasmid vector; the KISS1 sequence is connected to the 5' end of the GnRH sequence.
2. The anti-GnRH recombinant plasmid according to claim 1, Features: The plasmid vector is inserted with four GnRH sequences connected by flexible GS Linker; the repeated GnRH amino acid sequence containing GS Linker is shown in SEQ ID NO.
3.
3. The anti-GnRH recombinant plasmid according to claim 2, Features: The t-PA signal peptide sequence, PADRE sequence and KISS1 sequence are inserted into the 5' end of the fourth GnRH sequence; the amino acid sequence of the t-PA signal peptide is shown in SEQ ID NO.4; the amino acid sequence of PADRE is shown in SEQ ID NO.5; and the amino acid sequence of KISS1 is shown in SEQ ID NO.
6.
4. The anti-GnRH recombinant plasmid according to claim 1, Features: The plasmid vector is a eukaryotic plasmid vector pVAX1.
5. An anti-GnRH mRNA vaccine, Features: It comprises mRNA prepared by using the anti-GnRH recombinant plasmid according to any one of claims 1 to 4; the mRNA sequence is shown as SEQ ID NO.
7.
6. The anti-GnRH mRNA vaccine according to claim 5, Features: Also included are lipid nanoparticles.
7. The anti-GnRH mRNA vaccine according to claim 6, Features: The lipid nanoparticles include SM102, DSPC, cholesterol and PEG2000-DMG in a molar ratio of 50:10:38.5:1.
5.
8. A method for preparing an anti-GnRH mRNA vaccine, It is characterized in that The following steps are involved: An anti-GnRH recombinant plasmid was prepared, subjected to enzyme linearization treatment, and used as an in vitro transcription template for an in vitro transcription reaction. The obtained mRNA was encapsulated by lipid nanoparticles to obtain an anti-GnRH mRNA vaccine.
9. Use of the anti-GnRH recombinant plasmid according to any one of claims 1 to 4 or the anti-GnRH mRNA vaccine according to any one of claims 5 to 7 in the preparation of a product for treating hormone-dependent tumors.
10. Use of the anti-GnRH recombinant plasmid according to any one of claims 1 to 4 or the anti-GnRH mRNA vaccine according to any one of claims 5 to 7 in controlling the reproductive capacity of mammals.
